MTOR and leukemia: Further, rapamycin‐treated leukemia cells were presented with smaller cell and nuclear sizes, pharmacologically reversing the effect of Kmt2d knockdown, further providing experimental evidence for the role of the mTOR signaling pathway played in the tumorigenesis (Figure 4D).